BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 7875219)

  • 1. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.
    Ke Y; Li Y; Kapp JA
    Eur J Immunol; 1995 Feb; 25(2):549-53. PubMed ID: 7875219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
    Ke Y; Kapp JA
    J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
    Ishioka GY; Colon S; Miles C; Grey HM; Chesnut RW
    J Immunol; 1989 Aug; 143(4):1094-100. PubMed ID: 2787356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
    Rock KL; Clark K
    J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant.
    Rock KL; Fleischacker C; Gamble S
    J Immunol; 1993 Feb; 150(4):1244-52. PubMed ID: 8381832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination.
    Isaji K; Kawase A; Matono M; Guan X; Nishikawa M; Takakura Y
    J Control Release; 2009 May; 135(3):227-33. PubMed ID: 19331843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT; Umetsu DT; DeKruyff RH; Levy S
    J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injection of detergent-denatured ovalbumin primes murine class I-restricted cytotoxic T cells in vivo.
    Schirmbeck R; Böhm W; Reimann J
    Eur J Immunol; 1994 Sep; 24(9):2068-72. PubMed ID: 8088327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
    Ma H; Kapp JA
    Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OVA-specific CD8+ T cells do not express granzyme B during anterior chamber associated immune deviation.
    Ren Y; Yang P; Li B; Gao Y; Zhou H; Huang X; Zhu L; Kijlstra A
    Graefes Arch Clin Exp Ophthalmol; 2006 Oct; 244(10):1315-21. PubMed ID: 16538449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.
    Lipford GB; Hoffman M; Wagner H; Heeg K
    J Immunol; 1993 Feb; 150(4):1212-22. PubMed ID: 7679422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.
    Newman MJ; Wu JY; Gardner BH; Munroe KJ; Leombruno D; Recchia J; Kensil CR; Coughlin RT
    J Immunol; 1992 Apr; 148(8):2357-62. PubMed ID: 1373166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
    Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
    Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune effector cells induced by complete Freund's adjuvant exert an inhibitory effect on antigen-specific type 2 T helper responses.
    Chuang YH; Chiang BL; Chou CC; Hsieh KH
    Clin Exp Allergy; 1997 Mar; 27(3):315-24. PubMed ID: 9088658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen.
    Rock KL; Rothstein L; Fleischacker C; Gamble S
    J Immunol; 1992 May; 148(10):3028-33. PubMed ID: 1578128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.
    Martinez-Kinader B; Lipford GB; Wagner H; Heeg K
    Immunology; 1995 Oct; 86(2):287-95. PubMed ID: 7490131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V beta 5+ T cell receptors skew toward OVA+H-2Kb recognition.
    Dillon SR; Jameson SC; Fink PJ
    J Immunol; 1994 Feb; 152(4):1790-801. PubMed ID: 8120388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.